Profound Medical (PROF) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $2.6 million, up 82% year-over-year, driven by higher recurring revenue in the US and capital equipment sales overseas.

• Gross margin improved to 71% from 60% in Q1 2024, reflecting higher efficiency and product mix.

• Net loss widened to $10.7 million ($0.36/share) from $6.6 million ($0.27/share) year-over-year, mainly due to higher operating expenses for commercial expansion and R&D.

• Cash and equivalents stood at $46.4 million as of March 31, 2025.

• Strong clinical data from the CAPTAIN trial and new product launches, including the TULSA AI Volume Reduction Module, are expected to drive increased adoption.

Financial highlights

• Q1 2025 revenue was $2.6 million, with $1.8 million from recurring revenue and $820,000 from capital equipment sales.

• Gross margin rose to 71% from 60% year-over-year.

• Operating expenses increased to $13 million from $8.7 million in Q1 2024, reflecting higher R&D and SG&A.

• Net loss was $10.7 million ($0.36/share) in Q1 2025 versus $6.6 million ($0.27/share) in Q1 2024.

• Cash used in operations was $8.3 million in Q1 2025.

Outlook and guidance

• Management reaffirmed full-year revenue growth guidance of 70%-75% over 2024, expecting a back-end loaded year due to the transition from a placement to a capital sales model.

• Pipeline growth, increased patient demand, and new reimbursement codes are expected to support guidance.

• Anticipated full release of the TULSA AI Volume Reduction Module in Q4 2025.

• Existing cash and product sales expected to fund operations for at least the next 12 months.

• Expenses anticipated to rise as commercialization of TULSA-PRO and Sonalleve continues.